FIGURE 1

Mean Rat Pharmacokinetics of Two Formulations of LAP HCV active agent Dosed Intramuscular (IM) and Subcutenaous (SC)




FIGURE 2

Dog Pharmacokinetics of a Poloxamer 188 based Formulation of LAP HCV active agent Dosed Intramuscular (IM) at 100 mg/kg




FIGURE 3

Dog Pharmacokinetics of a Poloxamer 188 based Formulation of LAP HCV active agent Dosed Intramuscular (IM) at 100 mg/kg




FIGURE 4

Dog Pharmacokinetics of a Tween-20 based Formulation of LAP HCV active agent Dosed Intramuscular (IM) at 10 mg/kg




FIGURE 5

Dog Pharmacokinetics of a Tween 80 Formulation of LAP HCV active agent Dosed Intramuscular (IM) at 10 mg/kg

